RPRX Stock Analysis: Royalty Pharma | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 39.044m USD | 12M Return: 81.9% | GB00BMVP7Y09 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 211M
EPS Trend: 73.2%
Qual. Beats: 3
Rev. Trend: 81.3%
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 6.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Royalty Pharma plc (NASDAQ: RPRX) is a New York-based biopharmaceutical royalty acquisition and innovation funding company founded in 1996. Its portfolio includes royalties on approximately 35 marketed therapies and 20 development-stage product candidates spanning therapeutic areas such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company also maintains a research and development funding collaboration to advance JNJ-4804, an investigational treatment for autoimmune diseases. As a large-cap health care company within the pharmaceuticals sub-industry, Royalty Pharma operates under a unique business model in which it purchases royalty interests on drug sales-rather than developing or commercializing drugs itself-providing upfront capital to biopharmaceutical innovators in exchange for a share of future product revenue. This royalty-based structure allows the company to participate in the upside of successful therapies without bearing the typical risks and costs of drug development and commercialization.
- Imfinzi and other key royalties drive portfolio cash flow growth
- New royalty acquisitions expand biopharmaceutical royalty pipeline
- Rising interest rates boost investment income on royalty portfolio
| Net Income: 672.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 2.78 > 1.0 |
| NWC/Revenue: 13.24% < 20% (prev 56.12%; Δ -42.88% < -1%) |
| CFO/TA 0.15 > 3% & CFO 2.96b > Net Income 672.1m |
| Net Debt (8.04b) to EBITDA (1.57b): 5.13 < 3 |
| Current Ratio: 1.29 > 1.5 & < 3 |
| Outstanding Shares: last quarter (556.9m) vs 12m ago -0.49% < -2% |
| Gross Margin: 87.29% > 18% (prev 78.88%; Δ 8.41% > 0.5%) |
| Asset Turnover: 13.49% > 50% (prev 12.15%; Δ 1.34% > 0%) |
| Interest Coverage Ratio: 4.21 > 6 (EBIT TTM 1.56b / Interest Expense TTM 371.5m) |
| A: 0.02 (Total Current Assets 1.53b - Total Current Liabilities 1.18b) / Total Assets 19.5b |
| B: 0.13 (Retained Earnings 2.50b / Total Assets 19.5b) |
| C: 0.08 (EBIT TTM 1.56b / Avg Total Assets 19.4b) |
| D: 0.71 (Book Value of Equity 6.84b / Total Liabilities 9.67b) |
| Altman-Z'' = 1.82 = BBB |
As of November 10, 2026, the stock is trading at USD 68.77 with a total of 3,675,372 shares traded. Over the past week, the price has changed by +3.38%, over one month by +20.80%, over three months by +19.11% and over the past year by +81.90%.
Current recommended Stop Loss: 66.70 (which is 3% or 1.3 ATR below the current price).
Royalty Pharma has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy RPRX.
- StrongBuy: 5
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 65.4 | -4.9% |
P/E Trailing = 44.1634
P/E Forward = 34.4828
P/S = 14.9212
P/B = 3.0708
P/EG = 1.5737
Revenue TTM = 2.62b USD
EBIT TTM = 1.56b USD
EBITDA TTM = 1.57b USD
Long Term Debt = 8.57b USD (from longTermDebt, last fiscal year)
Short Term Debt = 997.0m USD (from shortTermDebt, last quarter)
Debt = 8.59b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 8.04b USD (calculated: Debt 8.59b - CCE 544.9m)
Enterprise Value = 47.1b USD (39.0b + Debt 8.59b - CCE 544.9m)
Interest Coverage Ratio = 4.21 (Ebit TTM 1.56b / Interest Expense TTM 371.5m)
EV/FCF = 15.91x (Enterprise Value 47.1b / FCF TTM 2.96b)
FCF Yield = 6.29% (FCF TTM 2.96b / Enterprise Value 47.1b)
FCF Margin = 113.1% (FCF TTM 2.96b / Revenue TTM 2.62b)
Net Margin = 25.68% (Net Income TTM 672.1m / Revenue TTM 2.62b)
Gross Margin = 87.29% ((Revenue TTM 2.62b - Cost of Revenue TTM 332.6m) / Revenue TTM)
Gross Margin QoQ = 91.01% (prev 60.21%)
Tobins Q-Ratio = 2.42 (Enterprise Value 47.1b / Total Assets 19.5b)
Interest Expense / Debt = 4.33% (Interest Expense 371.5m / Debt 8.59b)
Taxrate = 41.78% (553.2m / 1.32b)
NOPAT = 911.1m (EBIT 1.56b * (1 - 41.78%))
Current Ratio = 1.29 (Total Current Assets 1.53b / Total Current Liabilities 1.18b)
Debt / Equity = 1.26 (Debt 8.59b / totalStockholderEquity, last quarter 6.84b)
Debt / EBITDA = 5.13 (Net Debt 8.04b / EBITDA 1.57b)
Debt / FCF = 2.72 (Net Debt 8.04b / FCF TTM 2.96b)
Total Stockholder Equity = 6.76b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.46% (Net Income 672.1m / Total Assets 19.5b)
RoE = 9.94% (Net Income TTM 672.1m / Total Stockholder Equity 6.76b)
RoCE = 10.21% (EBIT 1.56b / Capital Employed (Equity 6.76b + L.T.Debt 8.57b))
RoIC = 4.76% (NOPAT 911.1m / Invested Capital 19.1b)
WACC = 4.84% (E(39.0b)/V(47.6b) * Re(5.35%) + D(8.59b)/V(47.6b) * Rd(4.33%) * (1-Tc(0.42)))
Discount Rate = 5.35% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -92.06 | Cagr: -3.04%
[DCF] Terminal Value 77.97% ; FCFF base≈2.74b ; Y1≈3.14b ; Y5≈4.62b
[DCF] Fair Price = 138.0 (EV 69.5b - Net Debt 8.04b = Equity 61.5b / Shares 445.3m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 73.24 | EPS CAGR: 7.71% | SUE: 0.99 | # QB: 3
Revenue Correlation: 81.28 | Revenue CAGR: 4.67% | SUE: -0.76 | # QB: 0
EPS current Quarter (2027-03-31): EPS=1.30 | Chg30d=+0.78% | Revisions=+25% | Analysts=1
EPS current Year (2026-12-31): EPS=5.32 | Chg30d=-0.40% | Revisions=+0% | GrowthEPS=+10.2% | GrowthRev=+7.7%
EPS next Year (2027-12-31): EPS=5.81 | Chg30d=+1.31% | Revisions=+50% | GrowthEPS=+9.2% | GrowthRev=+9.1%
[Analyst] Revisions Ratio: +44% (up=5, down=1)